Patents by Inventor Hassibullah Akeefe

Hassibullah Akeefe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11739345
    Abstract: Provided herein are methods of treating phenylketonuria by normalizing levels of amino acids, neurotransmitters, and neurotransmitter metabolites in a subject having phenylketonuria.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: August 29, 2023
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Geoffrey Berguig, Rajeev Mahimkar, Hassibullah Akeefe, Peter Colosi
  • Publication number: 20180355021
    Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
    Type: Application
    Filed: June 8, 2018
    Publication date: December 13, 2018
    Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
  • Publication number: 20170174747
    Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
    Type: Application
    Filed: March 9, 2017
    Publication date: June 22, 2017
    Inventors: MARC BELLOTTI, H. BRYAN BREWER, HASSIBULLAH AKEEFE, ADAM PAUL CONNER, TIMOTHY JON PERLMAN
  • Publication number: 20160324925
    Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 10, 2016
    Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
  • Publication number: 20140107029
    Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
    Type: Application
    Filed: December 19, 2013
    Publication date: April 17, 2014
    Applicant: HDL Therapeutics
    Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
  • Publication number: 20140050763
    Abstract: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating modified viral particles with reduced infectivity and enhanced antigenicity. The present invention provides vaccine compositions, comprising these modified viral particles with reduced infectivity and enhanced antigenicity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and/or one or more types of virus.
    Type: Application
    Filed: October 30, 2013
    Publication date: February 20, 2014
    Applicant: ELI LILLY & COMPANY
    Inventors: BILL E. CHAM, JO-ANN B. MALTAIS, MARC BELLOTTI, ADAM PAUL CONNER, HASSIBULLAH AKEEFE, MOIZ KITABWALLA
  • Patent number: 8637460
    Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: January 28, 2014
    Assignee: HDL Therapeutics LLC
    Inventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
  • Patent number: 8506968
    Abstract: Described is a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases such as SARS, in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating immunogenic modified, partially delipidated viral particles with reduced infectivity. The present invention provides delipidated viral vaccine compositions, such as therapeutic vaccine compositions, comprising these modified, partially delipidated viral particles with reduced infectivity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism or, in case of a therapeutic vaccine, to treat or alleviate infection against the lipid-containing infections viral organism.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: August 13, 2013
    Assignee: Eli Lilly and Company
    Inventors: Hassibullah Akeefe, Moiz Kitabwalla
  • Patent number: 8435531
    Abstract: The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from cancer cells, thereby creating a modified cancer cell particle. Upon delipidation of the cancer cells, a portion of the cancer cell antigens remain intact. These exposed antigens, or epitopes, foster and promote antibody production. The resulting modified cancer cell particle, or portions of the cancer cell, initiate a positive immunogenic response when administered to an animal or human and help to treat, prevent or delay the onset of cancer. The present invention provides autologous and heterologous vaccine compositions comprising the modified cancer cell with a pharmaceutically acceptable carrier. The present invention provides method of administering these vaccines to treat, prevent or delay the onset of cancer.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: May 7, 2013
    Assignee: Eli Lilly and Company
    Inventors: Moiz Kitabwalla, Hassibullah Akeefe
  • Publication number: 20130052167
    Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
    Type: Application
    Filed: August 31, 2012
    Publication date: February 28, 2013
    Applicant: HDL Therapeutics
    Inventors: Marc BELLOTTI, H. Bryan BREWER, JR., Hassibullah AKEEFE, Adam Paul CONNER, Timothy Jon PERLMAN
  • Patent number: 8268787
    Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: September 18, 2012
    Assignee: HDL Therapeutics
    Inventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
  • Publication number: 20110318423
    Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
    Type: Application
    Filed: August 31, 2011
    Publication date: December 29, 2011
    Applicant: HDL THERAPEUTICS
    Inventors: Marc Bellotti, H. Bryan Brewer, JR., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
  • Patent number: 8048015
    Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: November 1, 2011
    Assignee: HDL Therapeutics
    Inventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
  • Patent number: 8030281
    Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: October 4, 2011
    Assignee: HDL Therapeutics
    Inventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
  • Publication number: 20110150929
    Abstract: Described is a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases such as SARS, in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating immunogenic modified, partially delipidated viral particles with reduced infectivity. The present invention provides delipidated viral vaccine compositions, such as therapeutic vaccine compositions, comprising these modified, partially delipidated viral particles with reduced infectivity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism or, in case of a therapeutic vaccine, to treat or alleviate infection against the lipid-containing infections viral organism.
    Type: Application
    Filed: December 28, 2009
    Publication date: June 23, 2011
    Applicant: Eli Lilly and Company
    Inventors: Hassibullah Akeefe, Moiz Kitabwalla
  • Publication number: 20100215698
    Abstract: The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from cancer cells, thereby creating a modified cancer cell particle. Upon delipidation of the cancer cells, a portion of the cancer cell antigens remain intact. These exposed antigens, or epitopes, foster and promote antibody production. The resulting modified cancer cell particle, or portions of the cancer cell, initiate a positive immunogenic response when administered to an animal or human and help to treat, prevent or delay the onset of cancer. The present invention provides autologous and heterologous vaccine compositions comprising the modified cancer cell with a pharmaceutically acceptable carrier. The present invention provides method of administering these vaccines to treat, prevent or delay the onset of cancer.
    Type: Application
    Filed: May 6, 2010
    Publication date: August 26, 2010
    Applicant: Eli Lilly and Company
    Inventors: Moiz Kitabwalla, Hassibullah Akeefe
  • Patent number: 7740872
    Abstract: The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from cancer cells, thereby creating a modified cancer cell particle. Upon delipidation of the cancer cells, a portion of the cancer cell antigens remain intact. These exposed antigens, or epitopes, foster and promote antibody production. The resulting modified cancer cell particle, or portions of the cancer cell, initiate a positive immunogenic response when administered to an animal or human and help to treat, prevent or delay the onset of cancer. The present invention provides autologous and heterologous vaccine compositions comprising the modified cancer cell with a pharmaceutically acceptable carrier. The present invention provides method of administering these vaccines to treat, prevent or delay the onset of cancer.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: June 22, 2010
    Assignee: Eli Lilly and Company
    Inventors: Moiz Kitabwalla, Hassibullah Akeefe
  • Publication number: 20090017069
    Abstract: Described is a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases such as SARS, in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating immunogenic modified, partially delipidated viral particles with reduced infectivity. The present invention provides delipidated viral vaccine compositions, such as therapeutic vaccine compositions, comprising these modified, partially delipidated viral particles with reduced infectivity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism or, in case of a therapeutic vaccine, to treat or alleviate infection against the lipid-containing infections viral organism.
    Type: Application
    Filed: April 18, 2008
    Publication date: January 15, 2009
    Applicant: Lipid Sciences, Inc.
    Inventors: Hassibullah Akeefe, Moiz Kitabwalla
  • Publication number: 20080234621
    Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
    Type: Application
    Filed: March 24, 2008
    Publication date: September 25, 2008
    Applicant: Lipid Sciences, Inc.
    Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
  • Publication number: 20080230465
    Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
    Type: Application
    Filed: March 24, 2008
    Publication date: September 25, 2008
    Applicant: Lipid Sciences, Inc.
    Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman